Combined treatment with IL-10 and PD-1 blockers enhances the expansion and function of tumor-infiltrating CD8+ T cells, resulting in a synergistic anti-tumor effect in metastatic melanoma and ovarian cancer (189). This evidence concerns the gene CD8A and neoplasm.